Oral antiviral drugs under development for COVID-19 patients with mild symptoms are being eyed as potential game changers in the fight against the novel coronavirus. Currently, only intravenous ...

Onconova Therapeutics Inc ( (TRAW) ) has released its Q3 earnings. Here is a breakdown of the information Onconova Therapeutics Inc presented ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the ...

If authorised by regulators, molnupiravir would be the first oral antiviral medication for Covid-19. The pill, which was originally developed to treat influenza, is designed to introduce errors ...

In December 2021, two oral antiviral medications received emergency use authorization (EUA) from the U.S. Food and Drug Administration for the treatment of patients with mild-to-moderate COVID-19.

Continued investment from big pharma and a slew of new drugs with novel mechanisms of action are fueling investor interest in the antiviral space ... the isatoribine oral pro-drug (ANA975 ...

For those who do become unwell, the currently available antiviral drugs are virus-specific and ... host-directed, once-daily oral antiviral for the treatment of COVID-19 patients, with ...

A generic pill has been shown to reduce hospitalisation rates in high-risk patients with early COVID-19, potentially offering a low-cost alternative to oral antivirals from Merck & Co and others ...

Antiviral drugs can be used to block the herpes virus’s ability to make copies of itself, bringing the infection under control faster. Most cases of oral herpes are caused by herpes simplex ...

The results, published in The Journal of Controlled Release, may lead to a long-acting, refillable implant that delivers an HIV antiviral medication, Islatravir, into humans living with human ...

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, ...